Source-grounded facts extracted from BiomX Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Roy Rousso was appointed as Chief Business Officer at BiomX Inc..
“On May 27, 2026, the Board of Directors of BiomX Inc. (“we,” “us,” “our,” “BiomX” or the “Company”) appointed Mr. Roy Rousso, to serve as the Chief Business Officer, effective July 1, 2026.”
BiomX Inc. entered into Stock Purchase & Assignment Agreement with Mandragola Ltd (effective 2026-04-13).
“On April 13, 2026, the Company entered into and simultaneously closed on a Stock Purchase & Assignment Agreement (the “SPA”) with Mandragola”
BiomX Inc. completed an acquisition involving Mandragola Ltd for a cash payment of Seven Hundred Fifty Thousand Dollars ($750,000); the issuance of an unsecured convertible promissory note in the principal amount of Three Mil (closed 2026-04-13).
“delivery. In consideration for the Purchased Shares, the Company agreed to the following consideration to Mandragola: (i) a cash payment of Seven Hundred Fifty Thousand Dollars ($750,000), of which Four Hundred Fifty Thousand ($450,000) was advanced by the Company; (ii) the issuance of an unsecured convertible promissory note in the principal amount of Three”
BiomX Inc. entered into Stock Purchase Agreement with Water IO Ltd. valued at $1,250,000 (effective 2026-04-10).
“On April 10, 2026, BiomX Inc. (NYSE American: PHGE) (the “Company”) entered into and simultaneously closed a definitive Stock Purchase Agreement (the “SPA”) with Water IO Ltd. (“Water IO”), a publicly traded Israeli company listed on the Tel Aviv Stock Exchange, pursuant to which the Company acquired 100% of the issued and outstanding share capital of Zorro Net Ltd.”
BiomX Inc. completed an acquisition involving Water IO Ltd. for 1,300,000 shares of common stock ; and a non-convertible promissory note in the amount of $1,250,000 (closed 2026-04-10).
“active engagements with Elbit Systems Ltd (TASE/Nasdaq: ESLT) and other top Israel’s preeminent defense prime contractors. As consideration, the Company issued to Water IO: (i) 1,300,000 shares of common stock ; and (ii) a non-convertible promissory note in the amount of $1,250,000 , bearing interest at the short-term applicable federal rate, payable July 7, 2026.”
BiomX Inc. entered into Option and Undertaking Agreement with Mandragola Ltd (effective 2026-03-31).
“On March 31, 2026, BiomX Inc., a Delaware corporation (“BiomX” or the “Company”)) and Mandragola Ltd, a company formed under the laws of the State of Israel (“Mandragola), entered into an Option and Undertaking Agreement (the “Option Agreement”)”
BiomX Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).
“March 25, 2026, BiomX, Inc, a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company t”
BiomX Inc. amended Warrant Amendment with the Investor (effective 2026-03-13).
“On March 13, 2026, the Company and the Investor entered into an amendment to the Warrant (the “Warrant Amendment”), pursuant to which, the Investor and the Company agreed to (i) amend the term of the Warrant, such that the Warrant will expire on December 31, 2026, (ii) reduce the exercise price of the Warrant from $2.00 to $1.00 per share, and (iii) revise the method of determining the number of shares of Common Stock issuable upon a cashless exercise of the Warrant such that the number of shares of Common Stock issuable upon cashless exercise will be determined by reference, where applicable, to the lowest VWAP on the five (5) trading days immediately preceding the date on which the notice of exercise is submitted to the Company, rather than the VWAP on the day immediately preceding the date on which the notice of exercise is submitted.”
BiomX Inc. completed a disposition involving Trustee (closed 2026-02-04).
“On February 4, 2026, the Trustee notified BiomX Ltd.’s Chief Executive Officer and Chief Financial Officer that their roles as officers of BiomX Ltd. had been terminated. The Company determined that the termination is considered as a change of control as of February 4, 2026, and that BiomX Ltd. should be deconsolidated from the Company’s consolidated financial statements. The deconsolidation of BiomX Ltd. is considered a disposition of a significant amount of assets under Item 2.01 of Form 8-K.”
BiomX Inc.: Filed Certificate of Designations for Series Y Convertible Preferred Stock, creating a new series of preferred stock with specific rights and preferences (effective 2026-01-13).
“On January 13, 2026, the Company filed a Certificate of Designations of Series Y Convertible Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware”
BiomX Inc. entered into a equity purchase (effective 2026-01-13).
“On January 13, 2026, the Company issued 3,300 shares of the Preferred Stock.”
BiomX Inc. terminated Lease Agreement with ARE-708 Quince Orchard, LLC (effective 2025-12-31).
“On December 31, 2025, APT entered into a Seventh Amendment to Lease Agreement (the “Seventh Amendment”) with the Landlord in settlement of such claims. Pursuant to the Seventh Amendment, among other things, (i) the Lease was terminated effective December 31, 2025”
BiomX Inc. entered into Securities Purchase Agreement with an investor valued at $3.0 million (effective 2025-12-26).
“On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.”
BiomX Inc.: Board approved a 1:19 reverse stock split and authorized filing of a certificate of amendment to the certificate of incorporation, effective 12:01 a.m. ET on November 25, 2025 (effective 2025-11-25).
“On November 13, 2025, the Board approved a one-for-nineteen (1:19) reverse stock split (the “Reverse Stock Split”) of the outstanding shares of Common Stock, and authorized the filing of a certificate of amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”) to effect the Reverse Stock Split. The Company plans to file the Certificate of Amendment to effect the Reverse Stock Split as of 12:01 a.m. Eastern Time on November 25, 2025 (the “Effective Time”).”
Marina Wolfson was appointed as Chief Financial Officer at BiomX Inc..
“following Ms. Marina Wolfson’s return from maternity leave”
Avraham Gabay departed as Interim Chief Financial Officer at BiomX Inc..
“Effective May 31, 2024, Mr. Avraham Gabay’s term as Interim Chief Financial Officer of the Company will conclude”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.